Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 22, 2025, titled "Zydus announces USFDA Orphan Drug Designation to Usnoflast for the treatment of Amyotrophic Lateral Sclerosis (ALS)".
Press Release Jan 22 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that the USFDA has granted Orphan Drug Designation to Usnoflast for treating amyotrophic lateral sclerosis (ALS). This designation provides eligibility for development incentives, including tax credits and potential marketing exclusivity upon FDA approval. The company emphasizes its commitment to developing Usnoflast to address the urgent needs of ALS patients, who face severe health challenges.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 18 2025
- Press Release Jan 07 2025
- Press Release Dec 19 2024
- Press Release Nov 12 2024
- Press Release Oct 23 2024
Later from Zydus Lifesciences
- Press Release Jan 26 2025
- Press Release Jan 30 2025
- Press Release Feb 05 2025
- Press Release Feb 12 2025
- Press Release Feb 14 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences